Media
Media
Our latest announcements
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
30/06/2025
Hansa Biopharma: Increase in number of shares and votes
Regulatory press release
30/06/2025
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
Regulatory press release
25/06/2025
Hansa Biopharma has carried out a directed cash share issue of approx. mSEK 232 and entered into binding agreement to restructure debt held by NovaQuest, including set-off issue of USD 14.9 million
Regulatory press release
19/06/2025
Media articles
Insights
Collaboration across the continuum of care to improve equity for highly sensitized people in kidney transplantation
17/07/2024
A concerted collaboration to advance treatment options for people living with rare diseases
26/06/2024
Fueling the future: the role of biotech in advancing innovative science and delivering new medicines
02/05/2024
Addressing barriers to gene therapy treatment
31/01/2024
Patients' perspective
Life on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Patients' perspective
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
Global Corporate Affairs
Stephanie Kenney
Vice President Global Corporate Affairs
Email: [email protected]